Program
selinexor
Also written as “Selinexor”, “Selinexor (combination therapy)” and “Selinexor 40 mg”.
Its studies are mostly in Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Primary Myelofibrosis · Endometrial Neoplasms · Glioblastoma, led by 6 companies.
Drug pageSelinexor: every studyMany companies study it; this page follows only the 40 they lead. All 163 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Karyopharm Therapeuticsits history only | 317 open or running | phase 3since Oct 13, 2015 | May 16, 2012 | Dec 2026phase 3 · NCT04442022 |
| Antengeneits history only | 40 open or running | phase 2since Apr 30, 2019 | Apr 30, 2019 | none ahead |
| Oncotherapeuticsits history only | 22 open or running | phase 1since Aug 12, 2020 | Aug 12, 2020 | Apr 1, 2027phase 1 · NCT06225310 |
| AbbVieits history only | 11 open or running | phase 3since Nov 28, 2023 | Nov 28, 2023 | Dec 2027phase 3 · NCT06158841 |
| Qilu Pharmaceuticalits history only | 11 open or running | phase 3since Aug 13, 2025 | Aug 13, 2025 | Dec 2027phase 3 · NCT07138209 |
| Sarah Cannon Research Instituteits history only | 11 open or running | phase 2since Mar 1, 2021 | Mar 1, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 26 studies since May 16, 2012.
- Jun 10, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseKaryopharm Therapeutics · NCT04442022 · 501 enrolled · United States, China, Israel and more
- Aug 12, 2020Oncotherapeutics’ first study: phase 1 study in Multiple MyelomaNew to OncotherapeuticsOncotherapeutics · NCT04519476 · 22 planned · United States
- Sep 9, 2020Phase 2 study in Primary MyelofibrosisKaryopharm Therapeutics · NCT04562870 · 112 enrolled · United States, China, France and more
- Sep 14, 2020Phase 3 study in Primary MyelofibrosisKaryopharm Therapeutics · NCT04562389 · 353 enrolled · United States, Australia, Belgium and more
- Feb 22, 2021Phase 2 study in MelanomaKaryopharm Therapeutics · NCT04768881 · 15 enrolled · United States
- Mar 1, 2021Sarah Cannon Research Institute’s first study: phase 2 study in Multiple MyelomaNew to Sarah Cannon Research InstituteSarah Cannon Research Institute · NCT04782687 · 73 enrolled · United States
- Apr 17, 2021Phase 2 study in Colorectal NeoplasmsKaryopharm Therapeutics · NCT04854434 · 13 enrolled · United States
- Feb 9, 2022Phase 2 study in Lymphoma, Large B-Cell, DiffuseAntengene · NCT05265975 · 54 enrolled · China
- Apr 26, 2022Phase 1 study in Lymphoma, Large B-Cell, DiffuseAntengene · NCT05354362 · 7 enrolled · China
- Nov 3, 2022Phase 3 study in Endometrial NeoplasmsKaryopharm Therapeutics · NCT05611931 · 257 enrolled · United States, Australia, Belgium and more
- Jul 24, 2023Phase 2 study in Primary MyelofibrosisKaryopharm Therapeutics · NCT05980806 · 58 planned · United States, Belgium, Bulgaria and more
- Nov 7, 2023Phase 1 study in Multiple MyelomaOncotherapeutics · NCT06225310 · 30 planned · United States
- Nov 28, 2023AbbVie’s first study: phase 3 study in Multiple MyelomaNew to AbbVieAbbVie · NCT06158841 · 421 enrolled · United States, Australia, Austria and more
- Aug 13, 2025Qilu Pharmaceutical’s first study: phase 3 study in RecurrenceNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07138209 · 228 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseKaryopharm Therapeutics · NCT04442022
- Dec 2026Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseKaryopharm Therapeutics · NCT02227251
- Apr 1, 2027Primary completion: phase 1 study in Multiple MyelomaOncotherapeutics · NCT06225310
- Jun 2027Primary completion: phase 2 study in Primary MyelofibrosisKaryopharm Therapeutics · NCT05980806
TargetBeta
“An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), ”NCIt, by rule
“Exportin-1 inhibitor”ChEMBL 37, by rule
Other programs on XPO1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| TQB3107 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 40 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07138209Recurrence · China | 3 | Recruiting | Qilu Pharmaceutical | Dec 2027 | 228 |
| NCT06158841Multiple Myeloma · United States, Australia, Austria and more | 3 | Active, not recruiting | AbbVie | Dec 2027 | 421 |
| NCT06225310Multiple Myeloma · United States | 1 | Recruiting | Oncotherapeutics | Apr 1, 2027 | 30 |
| NCT05980806Primary Myelofibrosis · United States, Belgium, Bulgaria and more | 2 | Recruiting | Karyopharm Therapeutics | Jun 2027 | 58 |
| NCT05611931Endometrial Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Karyopharm Therapeutics | May 22, 2026 | 257 |
| NCT05354362Lymphoma, Large B-Cell, Diffuse · China | 1 | Terminated | Antengene | Feb 6, 2023 | 7 |
| NCT05265975Lymphoma, Large B-Cell, Diffuse · China | 2 | Terminated | Antengene | Dec 31, 2024 | 54 |
| NCT04854434Colorectal Neoplasms · United States | 2 | Terminated | Karyopharm Therapeutics | Jun 24, 2022 | 13 |
| NCT04782687Multiple Myeloma · United States | 2 | Active, not recruiting | Sarah Cannon Research Institute | May 31, 2026 | 73 |
| NCT04768881Melanoma · United States | 2 | Terminated | Karyopharm Therapeutics | Sep 22, 2023 | 15 |
| NCT04562389Primary Myelofibrosis · United States, Australia, Belgium and more | 3 | Active, not recruiting | Karyopharm Therapeutics | Feb 20, 2026 | 353 |
| NCT04562870Primary Myelofibrosis · United States, China, France and more | 2 | Active, not recruiting | Karyopharm Therapeutics | Sep 2026 | 112 |
| NCT04519476Multiple Myeloma · United States | 1 | Recruiting | Oncotherapeutics | Dec 29, 2023 | 22 |
| NCT04442022Lymphoma, Large B-Cell, Diffuse · United States, China, Israel and more | 3 | Active, not recruiting | Karyopharm Therapeutics | Dec 2026 | 501 |
| NCT04414475Multiple Myeloma · Greece, Israel | 2 | Recruiting | Karyopharm Therapeutics | Jan 2028 | 127 |
| NCT04421378Glioblastoma · United States, Canada | 2 | Terminated | Karyopharm Therapeutics | Jul 3, 2023 | 74 |
| NCT04355676Coronavirus Infections | 2 | Withdrawn | Karyopharm Therapeutics | Aug 30, 2020 | 0 |
| NCT04349098Coronavirus Infections · United States, Austria, France and more | 2 | Completed | Karyopharm Therapeutics | Oct 5, 2020 | 190 |
| NCT04256707Carcinoma, Non-Small-Cell Lung · Israel | 2 | Completed | Karyopharm Therapeutics | Jul 31, 2024 | 80 |
| NCT03992339Lymphoma, Large B-Cell, Diffuse · China | 2 | Completed | Antengene | May 31, 2023 | 60 |
| NCT03944057Recurrence · China | 2 | Completed | Antengene | Feb 25, 2022 | 82 |
| NCT03555422Endometrial Neoplasms · United States, Belgium, Canada and more | 3 | Completed | Karyopharm Therapeutics | Jan 22, 2022 | 263 |
| NCT03110562Multiple Myeloma · United States, Australia, Austria and more | 3 | Completed | Karyopharm Therapeutics | Feb 18, 2020 | 402 |
| NCT02628704Multiple Myeloma · United States | 2 | Withdrawn | Karyopharm Therapeutics | Jun 2017 | 0 |
| NCT02606461Liposarcoma · United States, Belgium, Canada and more | 3 | Completed | Karyopharm Therapeutics | Oct 28, 2020 | 342 |
| NCT02431351Myelodysplastic Syndromes | 2 | Withdrawn | Karyopharm Therapeutics | Dec 2017 | 0 |
| NCT02389543Multiple Myeloma | 2 | Withdrawn | Karyopharm Therapeutics | Jan 2018 | 0 |
| NCT02367690Diabetic Foot · New Zealand | 2 | Withdrawn | Karyopharm Therapeutics | May 2015 | 0 |
| NCT02336815Multiple Myeloma · United States, Austria, Belgium and more | 2 | Completed | Karyopharm Therapeutics | Jul 26, 2019 | 202 |
| NCT02314247Lymphoma, T-Cell, Peripheral · Australia, Singapore | 2 | Terminated | Karyopharm Therapeutics | Jan 2016 | 16 |
| NCT02227251Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more | 2 | Active, not recruiting | Karyopharm Therapeutics | Dec 2026 | 244 |
| NCT02213133Carcinoma, Squamous Cell · United States, Canada | 2 | Terminated | Karyopharm Therapeutics | Dec 10, 2015 | 45 |
| NCT02146833Prostatic Neoplasms · United States | 2 | Terminated | Karyopharm Therapeutics | Apr 1, 2016 | 20 |
| NCT02138786Richter's Transformation · United States, Germany, Poland and more | 2 | Terminated | Karyopharm Therapeutics | Aug 31, 2016 | 27 |
| NCT02088541Leukemia, Myeloid, Acute · United States, Canada, Denmark and more | 2 | Completed | Karyopharm Therapeutics | Jan 8, 2018 | 317 |
| NCT02025985Ovarian Neoplasms · Belgium, Denmark | 2 | Completed | Karyopharm Therapeutics | Jan 24, 2017 | 116 |
| NCT01986348Glioblastoma · United States, Denmark, Netherlands | 2 | Terminated | Karyopharm Therapeutics | Jan 23, 2020 | 76 |
| NCT01896505Sarcoma · United States, Canada | 1 | Completed | Karyopharm Therapeutics | Oct 21, 2016 | 54 |
| NCT01607905Carcinoma, Squamous Cell · United States, Canada, Denmark | 1 | Completed | Karyopharm Therapeutics | Mar 15, 2016 | 192 |
| NCT01607892Hematologic Neoplasms · United States, Canada, Denmark | 1 | Completed | Karyopharm Therapeutics | Oct 13, 2015 | 286 |
How it is read
Names in the registry
- “Selinexor”, 32 entries
- “Selinexor (combination therapy)”, 3 entries
- “Selinexor 40 mg”, 2 entries
- “Selinexor 60 mg”, 2 entries
- “ATG-010”, 2 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 11 studies
- Lymphoma, Large B-Cell, Diffuse, 5 studies
- Primary Myelofibrosis, 3 studies
- Endometrial Neoplasms, 2 studies
- Glioblastoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.